The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type
Open accessAbstract
The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to produce glutamine. Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase. In contrast to liver tumors, MYC-induced lung tumors display increased expression of both Glul and Gls1 and accumulate glutamine. We also show that inhibition of Gls1 kills cells that overexpress MYC and catabolize glutamine. Our results suggest that the metabolic profiles of tumors are likely to depend on both the genotype and tissue of origin and have implications regarding the design of therapies targeting tumor metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, inhibiting glutamine entry into the TCA cycle can blunt tumor progression in a MYC-driven cancer model of liver cancer (Xiang et al., 2015; Yuneva et al., 2012) and a MYC-inducible Burkitt lymphoma model (Le et al., 2012; Xiang et al., 2015).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“MYC has been found to increase mRNA and protein levels of glutamine transporters as well as expression of the enzyme glutaminase, which catalyzes the first step in glutaminolysis (Gao et al., 2009; Wise et al., 2008; Yuneva et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“Second, although different oncogenes reprogram metabolism in different ways, the tissue in which the oncogene is expressed affects the execution of metabolic reprogramming.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“Transgenic MYC induces metabolic changes in both liver tumors and lung tumors but activates glutamine catabolism in lung tumors and glutamine synthesis in liver tumors.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“MYC-driven cancer cells exhibit enhanced glutamine utilization accompanied by increased expression of key glutaminolysis enzymes, including GLS1/GLS2 and GLUD1178–180.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [179]
In the citing paper
“For example, liver tumors with aberrant overexpression of MYC display enhanced glutamine oxidation and sensitivity to therapies that target glutamine catabolism relative to liver tumors driven by overexpression of MET (196).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [196]
In the citing paper
“furthermore, a similar accumulation of glucose-derived glutamine within the tumor tissue was observed in a mouse model of c-Met-driven liver cancer (Yuneva et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Yuneva et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,346
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,456
Flagged first, then by citations
2 of the 64 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 638
Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes
Matés, J. M., Campos-Sandoval, J. A., Santos-Jiménez, J. D. L., Segura, J. A., Alonso, F. J., & Márquez, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190416165004 · Cited by 41
Self-citationThe metabolic adaptation mechanism of metastatic organotropism
Wang, C., & Luo, D. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00223-4 · Cited by 40
Self-citationThe role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
Specific features of ß-catenin-mutated hepatocellular carcinomas
Dantzer, C., Dif, L., Vaché, J., Basbous, S., Billottet, C., & Moreau, V. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02849-7 · Cited by 42
13C Tracer Studies of Metabolism in Mouse Tumor Xenografts
Lane, A. N., Yan, J., & Fan, T. W. ‐. (2015) · BIO-PROTOCOL · doi:10.21769/bioprotoc.1650 · Cited by 39
Self-citationLactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review
Kiran, D., & Basaraba, R. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.624607 · Cited by 39
Targeting MYC at the intersection between cancer metabolism and oncoimmunology
Venkatraman, S., Balasubramanian, B., Thuwajit, C., Meller, J., Tohtong, R., & Chutipongtanate, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1324045 · Cited by 40
Sener, Z., Cederkvist, F. H., Volchenkov, R., Holen, H. L., & Skålhegg, B. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160291 · Cited by 39
Wu, Y., Yan, B., Xu, W., Guo, L., Wang, Z., Li, G., Hou, N., Zhang, J., & Ling, R. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.39936 · Cited by 37
Snaebjornsson, M. T., Poeller, P., Komkova, D., Röhrig, F., Schlicker, L., Winkelkotte, A. M., Chaves‐Filho, A. B., Al-Shami, K. M., Caballero, C. D., Koltsaki, I., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-024-01201-w · Cited by 37
Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
Bi, J., Wu, S., Zhang, W., & Mischel, P. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.002 · Cited by 37
In vivo cancer metabolism is defined by the nutrient microenvironment
Elia, I., & Fendt, S. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.53 · Cited by 37
Raninga, P. V., He, Y., Datta, K. K., Lu, X. M., Maheshwari, U. R., Venkat, P., Mayoh, C., Gowda, H., Kalimutho, M., Hooper, J. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.12.011 · Cited by 36
Choi, B.-H., Rawat, V., Högström, J., Burns, P. A., Conger, K. O., Özgürses, M. E., Patel, J. M., Mehta, T. S., Warren, A., Selfors, L. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110278 · Cited by 38
Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?
McCann, C. K., & Kerr, E. M. (2021) · Cancers · doi:10.3390/cancers13133351 · Cited by 36
Liu, X., Qin, H., Li, Z., Lv, Y., Feng, S., Zhuang, W., Quan, X., Guo, C., Chen, C., & Zhang, H. (2022) · European Respiratory Journal · doi:10.1183/13993003.00062-2022 · Cited by 35
Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer
Sharma, R., & Malviya, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188869 · Cited by 35
Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma
Ziki, R. A., & Colnot, S. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101077 · Cited by 36
Ha‐ras and β‐catenin oncoproteins orchestrate metabolic programs in mouse liver tumors
Unterberger, E. B., Eichner, J., Wrzodek, C., Lempiäinen, H., Luisier, R., Terranova, R., Metzger, U., Plummer, S. M., Knorpp, T., Braeuning, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28798 · Cited by 37
The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis
Link, J. M., & Hurlin, P. J. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.04.004 · Cited by 36
Rationale for mitochondria-targeting strategies in cancer bioenergetic therapies
José, C., & Rossignol, R. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.07.005 · Cited by 35
Nutrient availability shapes methionine metabolism in p16/ MTAP -deleted cells
Sanderson, S. M., Mikhael, P. G., Ramesh, V., Dai, Z., & Locasale, J. W. (2019) · Science Advances · doi:10.1126/sciadv.aav7769 · Cited by 36
Linden, C. V., & Corbet, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.016 · Cited by 34
The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?
Loponte, S., Lovisa, S., Deem, A. K., Carugo, A., & Viale, A. (2019) · Cancers · doi:10.3390/cancers11101574 · Cited by 36
Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle
Duraj, T., Carrión-Navarro, J., Seyfried, T. N., Garcia‐Romero, N., & Ayuso‐Sacido, Á. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101389 · Cited by 36
Immune Cell Metabolism in Tumor Microenvironment
Li, Y., Wan, Y. Y., & Zhu, B. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_5 · Cited by 34
Immunosurveillance encounters cancer metabolism
Chuang, Y., Tzeng, S., Ho, P., & Tsai, C. (2024) · EMBO Reports · doi:10.1038/s44319-023-00038-w · Cited by 33
Metabolic Regulation in Mitochondria and Drug Resistance
Pan, Y., Cao, M., Liu, J., Yang, Q. K., Miao, X., Go, V. L. W., Lee, P. W. N., & Xiao, G. G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6674-0_11 · Cited by 33
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
Bloedjes, T. A., de Wilde, G., & Guikema, J. E. J. (2021) · Cancers · doi:10.3390/cancers13030396 · Cited by 32
García‐Cañaveras, J. C., & Lahoz, A. (2021) · Cancers · doi:10.3390/cancers13133230 · Cited by 33
Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics
Marchetti, P., Guerreschi, P., Mortier, L., & Kluza, J. (2015) · International Journal of Cell Biology · doi:10.1155/2015/283145 · Cited by 39
Serra, M., Matteo, M. D., Serneels, J., Pal, R. R., Cafarello, S. T., Lanza, M., Sànchez‐Martìn, C., Evert, M., Castegna, A., Calvisi, D. F., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.06.003 · Cited by 31
Lee, H. M., Muhammad, N., Lieu, E. L., Cai, F., Mu, J., Ha, Y., Cao, G., Suchors, C., Joves, K., Chronis, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01066-z · Cited by 33
Oh, M. S., Abascal, J. W., Rennels, A. K., Salehi‐Rad, R., Dubinett, S. M., & Liu, B. (2025) · Cancers · doi:10.3390/cancers17061027 · Cited by 33
Glutamine, Glucose and other Fuels for Cancer
Ruiz-Pérez, M. V., Sánchez‐Jiménez, F., Alonso, F. J., Segura, J., Márquez, J., & Medina, M. Á. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990482 · Cited by 31
Self-citationHuang, L., Mao, X., Sun, C., Luo, Z., Song, X., Li, X., Zhang, R., Lv, Y., Chen, J., He, J., et al. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.05.068 · Cited by 31
Metabolic programming of tumor associated macrophages in the context of cancer treatment
Crezee, T., Rabold, K., de Jong, L., Jaeger, M., & Netea-Maier, R. T. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1114 · Cited by 31
MYC Ran Up the Clock: The Complex Interplay between MYC and the Molecular Circadian Clock in Cancer
Burchett, J. B., Knudsen-Clark, A. M., & Altman, B. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147761 · Cited by 32
Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma
Zhang, T., Cui, Y., Wu, Y., Meng, J., Han, L., Zhang, J., Zhang, C., Yang, C., Chen, L., Bai, X. L., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.852 · Cited by 31
Bark, J. M., Karpe, A. V., Doecke, J. D., Leo, P., Jeffree, R. L., Chua, B., Day, B. W., Beale, D. J., & Punyadeera, C. (2023) · Cancer Medicine · doi:10.1002/cam4.5857 · Cited by 31
Phua, L. C., Goh, S., Tai, D. W. M., Leow, W. Q., Alkaff, S. M. F., Chan, C. Y., Kam, J. H., Lim, T. K. H., & Chan, E. C. Y. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3475-6 · Cited by 31
Chen, L., Cui, H., Fang, J., Deng, H., Kuang, P., Guo, H., Wang, X., & Zhao, L. (2016) · Oncotarget · doi:10.18632/oncotarget.10579 · Cited by 30
Shen, T., Wang, H., Tang, B., Zhu, G., & Wang, X. (2023) · RNA Biology · doi:10.1080/15476286.2023.2216562 · Cited by 29
Mohammed, A., Biegert, G. W. G., Adamec, J., & Helikar, T. (2017) · Oncotarget · doi:10.18632/oncotarget.21127 · Cited by 30
Krysztofiak, A., Szymonowicz, K., Hlouschek, J., Xiang, K., Waterkamp, C., Larafa, S., Goetting, I., Vega-Rubín-de-Celis, S., Theiß, C., Matschke, V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103366 · Cited by 29
Cancer Cell Metabolism: There Is No ROS for the Weary
Dang, C. V. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0069 · Cited by 29
Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells
Santos-Jiménez, J. D. L., Campos-Sandoval, J. A., Márquez-Torres, C., Urbano-Polo, N., Brøndegaard, D., Martín‐Rufián, M., Lobo, C., Peñalver, A., Gómez-García, M. C., Martín-Campos, J., et al. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00712-y · Cited by 28
Self-citationVerhulst, E., Garnier, D., Meester, I. D., & Bauvois, B. (2022) · Cancers · doi:10.3390/cancers14030624 · Cited by 28
Cholesterol efflux pathways hinder KRAS-driven lung tumor progenitor cell expansion
Guilbaud, E., Barouillet, T., Ilié, M., Borowczyk, C., Ivanov, S., Sarrazy, V., Vaillant, N., Ayrault, M., Castiglione, A., Rignol, G., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.05.005 · Cited by 28
Zhou, W.-X., Chen, C., Liu, X., Li, Y., Lin, Y., Wu, X.-T., Kong, L., & Luo, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112980 · Cited by 28
Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
Suzuki, T., Kishikawa, T., Sato, T., Takeda, N., Sugiura, Y., Seimiya, T., Sekiba, K., Ohno, M., Iwata, T., Ishibashi, R., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00326-4 · Cited by 28
A glutamine ‘tug-of-war’: targets to manipulate glutamine metabolism for cancer immunotherapy
Pallett, L. J., Dimeloe, S., Sinclair, L. V., Byrne, A. J., & Schurich, A. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab010 · Cited by 28
Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?
Fidelito, G., Watt, M. J., & Taylor, R. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.778761 · Cited by 27
Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus
Silva, R. C. M. C., Lopes, M. F., & Travassos, L. H. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.11.001 · Cited by 27
Critical roles and clinical perspectives of RNA methylation in cancer
Li, G., Yao, Q., Liu, P., Zhang, H., Liu, Y., Li, S., Shi, Y., Li, Z., & Zhu, W. (2024) · MedComm · doi:10.1002/mco2.559 · Cited by 29
Kohe, S. E., Bennett, C., Gill, S. K., Wilson, M., McConville, C. M., & Peet, A. C. (2018) · Oncotarget · doi:10.18632/oncotarget.24168 · Cited by 27
Oxidative and Glycolytic Metabolism: Their Reciprocal Regulation and Dysregulation in Cancer
Cordani, M., Rumio, C., Bontempi, G., Strippoli, R., & Marcucci, F. (2025) · Cells · doi:10.3390/cells14151177 · Cited by 28
Network and systems biology: essential steps in virtualising drug discovery and development
Wierling, C., Keßler, T., Ogilvie, L. A., Lange, B. M. H., Yaspo, M., & Lehrach, H. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.07.002 · Cited by 26
Kohrogi, K., Hino, S., Sakamoto, A., Anan, K., Takase, R., Araki, H., Hino, Y., Araki, K., Sato, T., Nakamura, K., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003521 · Cited by 26
From Prokaryotes to Cancer: Glutamine Flux in Multicellular Units
Erez, A., & Kolodkin‐Gal, I. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.007 · Cited by 26
The lactylation-macrophage interplay: implications for gastrointestinal disease therapeutics
Che, X., Zhang, Y., Chen, X., Xie, G., Li, J., Xu, C., Zhang, C., Zhu, Y., & Yang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608115 · Cited by 26
Self-citationMYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance
Marengo, B., Garbarino, O., Speciale, A., Monteleone, L., Traverso, N., & Domenicotti, C. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7346492 · Cited by 25
Dietary intervention as a therapeutic for cancer
Morita, M., Kudo, K., Shima, H., & Tanuma, N. (2020) · Cancer Science · doi:10.1111/cas.14777 · Cited by 25
Proline dehydrogenase in cancer: apoptosis, autophagy, nutrient dependency and cancer therapy
Liu, Y., Mao, C., Liu, S., Xiao, D., Shi, Y., & Tao, Y. (2021) · Amino Acids · doi:10.1007/s00726-021-03032-5 · Cited by 25
AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity
Bloedjes, T. A., de Wilde, G., Khan, G. H., Ashby, C., Shaughnessy, J. D., Zhan, F., Houtkooper, R. H., Bende, R. J., van Noesel, C. J. M., Spaargaren, M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007383 · Cited by 26
Convergence of Cancer Metabolism and Immunity: an Overview
Dang, C. V., & Kim, J. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.194 · Cited by 25
Cytotoxin activity on Vero cells among Escherichia coli strains associated with diarrhea in cats
ABAAS, S., Franklin, A., Kühn, I., Ørskov, F., & Ørskov, I. (1989) · American Journal of Veterinary Research · doi:10.2460/ajvr.1989.50.08.1294 · Cited by 25
Yan, R., Cai, H., Zhou, X., Bao, G., Bai, Z., & Ge, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1344971 · Cited by 28
Metabolic adaptations in cancer progression
Peng‐Winkler, Y., & Fendt, S. (2025) · Physiological Reviews · doi:10.1152/physrev.00037.2024 · Cited by 25
McGrail, K., Granado‐Martínez, P., Esteve‐Puig, R., García-Ortega, S., Ding, Y., Sánchez‐Redondo, S., Fábrega, B. F., Hernández‐Losa, J., Canals, F., Manzano, À., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34907-0 · Cited by 25
Padinharayil, H., Rai, V., & George, A. (2023) · Cancers · doi:10.3390/cancers15041070 · Cited by 26
Stable isotope-resolved metabolomics based on mass spectrometry: Methods and their applications
Yu, D., Zhou, L., Liu, X., & Xu, G. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.116985 · Cited by 25
MYC and AMPK–Save Energy or Die!
Haikala, H. M., Anttila, J. M., & Klefström, J. T. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00038 · Cited by 25
Role and therapeutic targeting of glutamine metabolism in non‑small cell lung cancer (Review)
Zhou, L., Zhang, Q., Zhu, Q., Zhan, Y., Li, Y., & Huang, X. (2023) · Oncology Letters · doi:10.3892/ol.2023.13745 · Cited by 23
The fuel and engine: The roles of reprogrammed metabolism in metastasis of primary liver cancer
Zhu, W., Lü, M., Wang, X., Xu, Z., Gao, C., & Qin, L. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.016 · Cited by 25
Cancer Cell Metabolism as New Targets for Novel Designed Therapies
de Mas, I. M., Aguilar, E., Jayaraman, A., Polat, I. H., Martín-Bernabé, A., Bharat, R., Foguet, C., Milà, E., Papp, B., Centelles, J. J., et al. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.119 · Cited by 25
The mitochondrial dysfunction plays an important role in urethane-induced lung carcinogenesis
Du, G., Sun, T., Zhang, Y., Lin, H., Li, J., Liu, W., Wang, Y., Zhao, B., Li, H., & Liu, Y. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.031 · Cited by 24
mTOR Regulation of Metabolism in Hematologic Malignancies
Mirabilii, S., Ricciardi, M. R., & Tafuri, A. (2020) · Cells · doi:10.3390/cells9020404 · Cited by 24
Targeting Cancer Metabolism and Current Anti-Cancer Drugs
Sukjoi, W., Ngamkham, J., Attwood, P. V., & Jitrapakdee, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_2 · Cited by 23
Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC
Lee, J., Kang, J. H., Lee, S.-H., Lee, C. H., Son, J., & Kim, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.095 · Cited by 23
Wang, X., Xiao-xia, Y., Peng-Fei, S., Zong-Xue, Z., & Xiu-li, G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175323 · Cited by 23
On the Role of Glycolysis in Early Tumorigenesis—Permissive and Executioner Effects
Marcucci, F., & Rumio, C. (2023) · Cells · doi:10.3390/cells12081124 · Cited by 23
Regulation of Glucose Metabolism in Hepatocarcinogenesis by MicroRNAs
Reyes, R., Motiwala, T., & Jacob, S. T. (2014) · Gene Expression · doi:10.3727/105221614x13919976902093 · Cited by 22
Wilkie, M. D., Lau, A., Vlatković, N., Jones, T. M., & Boyd, M. T. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.05.018 · Cited by 22
Zhang, C., Hu, J., Sheng, L., Yuan, M., Wu, Y., Chen, L., Zheng, G., & Qiu, Z. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.01.004 · Cited by 22
Interactions between the metabolic reprogramming of liver cancer and tumor microenvironment
Yang, H., Li, J., Niu, Y., Zhou, T., Zhang, P., Liu, Y., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1494788 · Cited by 23
Zonation, Zonation, Zonation: The Real Estate of the Liver
Yasaka, T. M., Kim, C., Meadows, V., & Monga, S. P. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-042624-091820 · Cited by 28
Metabolic Constrains Rule Metastasis Progression
Roda, N., Gambino, V., & Giorgio, M. (2020) · Cells · doi:10.3390/cells9092081 · Cited by 22
NMR Methods for Determining Lipid Turnover via Stable Isotope Resolved Metabolomics
Lin, P., Dai, L., Crooks, D. R., Neckers, L. Μ., Higashi, R. M., Fan, T. W. ‐., & Lane, A. N. (2021) · Metabolites · doi:10.3390/metabo11040202 · Cited by 23
Self-citationPhysiological impact of in vivo stable isotope tracing on cancer metabolism
Grima-Reyes, M., Martinez-Turtos, A., Abramovich, I., Gottlieb, E., Chiche, J., & Ricci, J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101294 · Cited by 24
Divergent Roles of Mitochondria Dynamics in Pancreatic Ductal Adenocarcinoma
Carmona‐Carmona, C. A., Pozza, E. D., Ambrosini, G., Errico, A., & Dando, I. (2022) · Cancers · doi:10.3390/cancers14092155 · Cited by 23
Emerging approaches to target tumor metabolism
Ross, S. J., & Critchlow, S. E. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.001 · Cited by 21
Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications
Hosein, A. N., & Beg, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0699-5 · Cited by 21
Inferring cancer dependencies on metabolic genes from large-scale genetic screens
Lagziel, S., Lee, W. D., & Shlomi, T. (2019) · BMC Biology · doi:10.1186/s12915-019-0654-4 · Cited by 21
Inhibition of Anaplerotic Glutaminolysis Underlies Selenite Toxicity in Human Lung Cancer
Bruntz, R. C., Belshoff, A. C., Zhang, Y., Macêdo, J. K. A., Higashi, R. M., Lane, A. N., & Fan, T. W. ‐. (2019) · PROTEOMICS · doi:10.1002/pmic.201800486 · Cited by 21
Self-citationMuthu, M., Kumar, R., Khaja, A. S. S., Gilthorpe, J. D., Persson, J. L., & Nordström, A. (2019) · Cancers · doi:10.3390/cancers11121945 · Cited by 21
Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma
Khadka, S., Arthur, K., Barekatain, Y., Behr, E., Washington, M., Ackroyd, J. J., Crowley, K., Suriyamongkol, P., Lin, Y.-H., Pham, C.-D., et al. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00259-4 · Cited by 21
Zhou, S., Liu, R. R., Yuan, K., Yi, T., Zhao, X., Huang, C., & Wei, Y. (2012) · Mass Spectrometry Reviews · doi:10.1002/mas.21362 · Cited by 21
Chen, W., Dong, G., He, S., Xu, T., Wang, X., Liu, N., Zhang, W., Miao, C., & Sheng, C. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.101 · Cited by 21
Effects of Aging on Glucose and Lipid Metabolism in Mice
Lien, E. C., Vu, N., Westermark, A. M., Danai, L. V., Lau, A. N., Gültekin, Y., Kukurugya, M. A., Bennett, B. D., & Heiden, M. G. V. (2024) · Aging Cell · doi:10.1111/acel.14462 · Cited by 22
Metadata
- Authors
- Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., Chen, X., & Bishop, J. M.
- Affiliations
- University of California, San Francisco (US)
- University of Louisville (US)
- Johns Hopkins University (US)
- Universidad de Málaga (ES)
- Corresponding author
- Yuneva, Mariia O.
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 2
- Pages
- 157-170
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC3282107
- OpenAlex
- W2036659083
- Cited by
- 639
- References
- 64
- Citations by year
- 2026: 17 · 2025: 37 · 2024: 35 · 2023: 41 · 2022: 53 · 2021: 66 · 2020: 43 · 2019: 59 · 2018: 45 · 2017: 63 · 2016: 47 · 2015: 39 · 2014: 42 · 2013: 34 · 2012: 16
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R35CA044338, R01CA118434)
- National Institute of Neurological Disorders and Stroke (R21NS074151)
- National Center for Research Resources (P20RR018733)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- cancer metabolism, c-Myc, MET, glutamine catabolism, glutamine synthetase, glutaminase, GLS1, GLS2, liver tumors, lung cancer, genetic lesions, glutamine accumulation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Citric Acid Cycle, Glucokinase, Glucose, Glutamine, Humans, Immunohistochemistry, Isotope Labeling, Liver Neoplasms, Experimental, Lung Neoplasms, Immunoblotting, Blotting, Western, Proto-Oncogene Proteins c-myc, DNA Primers, Lactic Acid, Proto-Oncogene Proteins c-met, Nuclear Magnetic Resonance, Biomolecular, RNA Interference, Cell Line, Tumor, Mice, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
